CyFlow™ CD23 PE-DyLight™ 594
| Alternative Name: | BLAST-2, FcɛRII |
| Antigen: | CD23 |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | EBVCS-5 |
| Emission Maximum: | 618 nm |
| Excitation Maximum: | 593 nm |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | PE-DyLight™ 594 |
| Isotype: | IgG1 |
| Laser: | Blue , Green, Yellow |
| Regulatory Status: | CE IVD |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | AG271103 |
CE IVD
| Concentration Unit | µg/mL |
| Concentration | 50 |
| Quantity | 100 tests |
| Volume | 1.0 mL |
| Immunogen | EBV-transformed human cells |
| Background Information | CD23 (FcεRII, BLAST-2), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines. |
| Antigen Distribution | CD23 (FcεRII, BLAST-2), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines. |
| Usage | CE IVD usage Placeholder |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) BSA. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1991 Dec; 86(3):360‑6. < PMID: 1721010 > | Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int Immunol. 1996 Apr; 8(4):479‑90. < PMID: 8722638 > | Rumi C, Rutella S, Leone G, Bonini S: Fc‑RII/CD23 receptor on circulating human eosinophils. Blood. 1998 Apr 1; 91(7):2621‑2. < PMID: 9516167 > | Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL‑4, GM‑CSF, and IL‑4/GM‑CSF. Clin Mol Allergy. 2005 May 20; 3:6. < PMID: 15907205 > | Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1; 13(15‑1):4448‑55. < PMID: 17671129 > | Aleena A Gladkikh, Daria M Potashnikova, Victor Tatarskiy Jr, Margarita Yastrebova, Alvina Khamidullina, Natasha Barteneva, Ivan Vorobjev: Comparison of the mRNA expression profile of B‐cell receptor components in normal CD5‐high B‐lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70. CancerMed. 2017 Dec; 6(12):2984‐2997. < PMID: 29125235 >